Tagged with POLA

Poland Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore, he highlights the strategic importance of the nation for Chiesi globally, as well as his aspiration to further solidify the…

Poland Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore, he highlights the strategic importance of Poland in the region as the company’s footprint continues to grow and highlights the…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…

Poland Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments. Furthermore, he highlights the company’s international strategy and strong manufacturing capabilities, both for their own treatments and in the context…

Brazil Paulo Vitor de Andrade, founder and director of Grupo Polar, elaborates on his journey to build the Brazilian company of reference in cold chain solutions and the company’s relentless efforts to disseminate knowledge to improve the logistics environment in Brazil and globally. Grupo Polar is recognized as a reference in…

Poland Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio and exciting pipeline, new therapeutic areas, and his future aspirations for Angelini Poland. As the general manager for Poland at…

Poland Stefan Buguslawski, president of PEX Pharmasequence, a leading Polish healthcare consultancy and market research company, highlights the current obstacles facing the Polish healthcare market and the dynamics of the domestic pharmaceutical industry. He also discusses the innovative services they provide and how their offering will develop in the future. As…

Poland Piotr Ponikowski, president of the Polish Cardiac Society, discusses the positive steps Poland is taking to construct an effective program against cardiovascular disease as well as the importance of a structured national prevention strategy. Furthermore, he highlights the importance of the Society acting as a partner with the entire value…

Lithuania Šarūnas Narbutas, president at the Lithuanian Cancer Patients’ Coalition (POLA), explains the role of patients in shaping the Lithuanian healthcare system as well as the importance of having an integral approach when discussing with healthcare stakeholders to drive progress in the country. You hold a number of roles in different…

Poland Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself in the global pharmaceutical ecosystem. Moreover, he highlights the impact of global acquisitions and the niche area model they have…